The company’s CLEWICU artificial intelligence software ingests a large range of patient data by linking to electronic medical records, connected medical devices and vital sign monitors, with no need for additional data entry by ICU staff.
In addition to alerting providers to a patient’s potentially deteriorating condition as a diagnostic aid, the system’s real-time risk classification model also predicts which patients may not require any interventions within an eight-hour period.
The FDA also said the standalone CLEWICU software, based within the hospital or in the cloud, could help reduce contact between healthcare workers and COVID-19 patients through remote monitoring.
“By identifying high risk patients, prioritizing treatment based on patient acuity, and reducing the false alarm rate this likely provides better care for patients and reduces the strain on the ICU personnel,” the agency said in its letter granting the Emergency Use Authorization.
According to CLEW’s previous validation studies, the system was able to provide true positive alerts predicting oncoming respiratory failure or hemodynamic instability by a median of three-and-a-half hours.
The company previously submitted an application for a full 510(k) FDA clearance while the system undergoes testing at tele-ICU facilities at UMass Memorial Medical Center and the WakeMed health system in Raleigh, North Carolina.